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INTRODUCTION 
This book contains the submitted abstracts for the oral and poster free Communications accepted for 
presentation at the 13th Congress of the International Diabetes Federation. The abstracts have been 
reproduced in the form in which they were submitted. 
Abstracts for plenary lectures and symposia are not included. The manuscripts of these presentations 
will be published in the Proceedings of the Congress which may be ordered at the Elsevier desk at the 
Congress. 
The book is arranged with the oral free Communications at the front followed by the poster free 
Communications. The abstracts are arranged and indexed according to the Session in which they are 
presented. For example, ORA-015-003 refers to the third presentation in session of 15 of the oral free 
Communications and POS-003-172 refers to poster 172 in the third poster session. The poster 
presentation number also represents the poster board number, ie POS-003-172 will appear on poster 
board No. 172. For convenience, a preliminary programme is included in this book. The final 
Programme, which may contain some minor alterations, is included in the programme booklet in your 
satchel. 
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POS-002-024 
ISOPROTERENOL DECREASES ACTIVATION BY INSULIN OF INSULIN RECEPTOR KINASE 
IN INTACT RAT ADIPOCYTES. 
H.H. KLEIN1, S. MATTHAEI2, P.C. SCRIBA1 
Departments of Internal Medicine^University of Lübeck and 2University of Hamburg, FRG. 
It has been previously shown that ß-adrenergic agonists produce insulin(I)-resistance 
both in vivo and in vitro. We have studied the effect of isoproterenol(ISO) on I-binding 
and activation of insulin receptor kinase(IRK) in intact rat adipocytes. Cell concentra-
tion was <2xl03/ml in buffer containing 2%BSA and 40mM Hepes (pH 7.4). Preincubation with 
ISO (ltyiM) was for 30min at 37<>C. l 2 s I - I was then added to a fraction of the cells for 
15min at 37°C to measure I-binding. The other cells were exposed to various concentra-
tions of I for 15min at 37°C in order to activate the cellular IRK. IRK was then isolated 
and immunoprecipitated in the presence of Phosphatase inhibitors. Under these conditions, 
IRK-activity that resulted from exposure to insulin while the cells were intact, was pre-
served. It was subsequently measured in the presence of 0.5 /iM 32P-ATP and lmg/ml histone 
and was (fmol P into histone/pmol I-binding activity/min): 
Insulin(ng/ml): 0 4 20 500 
-ISO : 4.6+1.0 30.5+5.1 93.8+11.6 124.8+39.3 
+ISO : 4.3+1.1 22.8+2.5 66.1+ 1.0 112.0+27.8 
Mean values for trace I-binding to the cells were: -ISO:0,49+0.12; +180:0,45+0.08%. 
Conclusions: (1)Exposure of the cells to insulin stimulated IRK-activity 25-30fold. 
(2) Activation of IRK by I in intact cells was reduced up to 30% in the presence of ISO. 
(3) Only a minimal, i f any, reduction of I-binding to the cells was observed in the pre-
sence of ISO. (4)0ur data thus suggest that ISO reduces I-activation of IRK in intact 
cells on a post-binding level. 
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